title: Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
abstract: This study investigated whether domperidone could improve gastrointestinal symptoms in patients with Parkinson's disease who were receiving levodopa therapy. A total of 11 patients were studied. Following a baseline gastric emptying test, patients were treated with a starting dose of domperidone 20 mg p.o. q.i.d. A follow-up gastric emptying test was repeated at least 4 months after starting domperidone therapy. At the beginning and at each 3-month follow-up visit, symptoms of nausea, vomiting, anorexia, abdominal bloating, heartburn, regurgitation, dysphagia, and constipation were evaluated and scored on a scale of 0-3. The overall mean follow-up period was 3 years. Compared with their baseline evaluation, patients experienced a significant improvement in all symptoms (p < 0.05) except dysphagia and constipation. Gastric emptying of an isotope-labeled solid meal was significantly faster, with a baseline result of 60.2 +/- 6.4% retention of isotope 2 h after the meal compared with 37.0 +/- 2.2% retention during domperidone therapy (p < 0.05). Patients' global assessment of Parkinson's disease remained stable or improved. Serum prolactin was elevated in all patients after domperidone therapy (p < 0.05). Domperidone therapy significantly reduces upper gastrointestinal symptoms and accelerates gastric emptying of a solid meal, but does not interfere with response to antiparkinsonism treatment.
authors.affiliation: Department of Medicine, University of Virginia, Charlottesville, USA.
authors.forename: I
authors.initials: I
authors.lastname: Soykan
authors.forename: I
authors.initials: I
authors.lastname: Sarosiek
authors.forename: J
authors.initials: J
authors.lastname: Shifflett
authors.forename: G F
authors.initials: GF
authors.lastname: Wooten
authors.forename: R W
authors.initials: RW
authors.lastname: McCallum
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D004294:Domperidone / Q000494:pharmacology* / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005746:Gastric Emptying / Q000187:drug effects*; D005767:Gastrointestinal Diseases / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D012642:Selegiline / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D000978:Antiparkinson Agents; D018492:Dopamine Antagonists; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D004294:Domperidone; D002230:Carbidopa